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Osteoarthritis (OA) is a degenerative joint disease that pro-
gressively causes loss of joint function and is the leading
source of physical disability and impaired quality of life in in-
dustrialized nations. The burden of disease dramatically im-
pacts health care usage and leads to total joint replacement
in approximately a half-million Americans alone each year e
and such consequences on society worldwide are expected
to rise in coming decades with the continued expanding and
aging population.
There are no current interventions proven to restore car-
tilage or curtail the disease processes. Thus, OA often ul-
timately results in joint destruction, chronic pain, disability,
depression and social isolation. Multiple etiologic risk fac-
tors and pathophysiologic processes all contribute to the
progressive nature of the disease e and serve as targets
of behavioral and pharmacologic interventions. Risk fac-
tors, such as age, gender, trauma, overuse, genetics
and obesity each make contributions to initiate the process
of injury in different components of the joint; then the effec-
tor biochemical processes involving the cartilage, bone,
and synovium eventually intertwine and collectively dam-
age all three components as well (Fig. 1)1. These effects
on the tissues of all three joint compartments manifest
as articular cartilage breakdown, osteophyte formation,
subchondral sclerosis, bone marrow lesions and alter-
ations of the synovium on both morphologic and biochem-
ical levels often causing episodic synovitis. Thus, the
molecular and cytokine-based events that drive joint dam-
age in inﬂammatory arthritides have gradually emerged as
pathogenic paradigms in OA, and will be highly relevant to
the development of future OA therapeutics. With increas-
ing appreciation of the contribution of all three joint com-
partments to disease progression, current research in
OA pathogenesis, biomarkers and treatment has broad-
ened immensely in recent years. In this review, we will fo-
cus on emerging pathogenic concepts that will hopefully
help advance the search for effective disease-modifying
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S1Cartilage: a target and a protagonist
The synovium, bone, and cartilage are each well estab-
lished tissues impacted by the pathological mechanisms oc-
curring in OA. Local and intertwined abnormalities in these
compartments lead to progressive joint degeneration, yet
the cartilage has traditionally received the most attention in
the study ofOAbecause of the gross damage found in pathol-
ogy specimens and imaging studies, and themultitude of bio-
chemical processes that are activated. Key events occurring
in cartilage during the pathogenesis of OA include an imbal-
ance ofmetabolic and degradative signals, driven by cytokine
cascades and the production of inﬂammatory mediators.
Chondrocytes, as well as synovial cells, of OA patients pro-
duce increased levels of inﬂammatory cytokines, such as in-
terleukin-1b (IL-1b) and tumor necrosis factor-a (TNF-a),
which in turn decrease anabolic collagen synthesis and in-
crease catabolic (including matrix metalloproteinases or
MMPs) and other inﬂammatory mediators such as IL-8, IL-6,
prostaglandin E2 and nitric oxide (NO)2,3.
Coupled with the various activated degradative biochem-
ical pathways are often biomechanical derangements, such
as those seen in joint malalignment or obesity, which can
both predispose to and perpetuate OA. It is clear that the al-
tered biomechanics seen in OA induce and potentiate bio-
chemical changes and it has been shown that both static
and dynamic compression of cartilage explants tends to
up-regulate many molecules such as aggrecan, ﬁbronectin,
MMPs, aggrecanase-2 (ADAMTS-5), and c-fos, c-jun4,5.
Therefore, gene expression by chondrocytes in cartilage af-
ter injurious compression mimics in some ways that ob-
served after IL-1b stimulation, and may offer an
opportunity for pharmacological intervention. In addition,
mechanical stress, by both static and intermittent compres-
sion, increases NO production by chondrocytes as well as
nitric oxide synthase (NOS) expression. Therefore, in
vivo, NO production may be in part regulated by biome-
chanics6. In turn, NO contributes to articular cartilage dam-
age and plays multiple roles with respect to its effects on
chondrocytes. Overall, it promotes cartilage degradation
by inhibition of collagen and proteoglycan synthesis, MMP
activation, and increased susceptibility to other oxidant
injury.
Reactive oxygen species (ROS) have been implicated in
directly promoting chondrocyte apoptosis, catabolic pro-
cesses and matrix degradation. Thus two important patho-
genic events characteristic of OA chondrocytes,
premature senescence and apoptosis, appear to result
Fig. 1. Molecular pathogenesis of OA. Potential biomarkers and targets for disease modiﬁcation are released as a result of events in cartilage,
bone, and synovium. Figure adapted from Ref. 1.
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drive the concept that OA is a disease of premature aging
of the joint. Senescence is characterized by shortened telo-
meres, increased levels of B-galactosidase and decreased
ATP production from mitochondrial dysfunction11. These
changes have been demonstrated histologically in chondro-
cytes taken from OA patients12. Studies suggest that the
telomere shortening and reduced number and function of
mitochondria seen in OA chondrocytes are results of oxida-
tive stress. Other work implicates NO as an important medi-
ator in chondrocyte apoptosis, which is a common feature in
progressive OA. Immunohistochemistry of joint tissue from
OA patients co-localizes apoptotic areas with iNOS proteinFig. 2. Signiﬁcant synovial thickening, bone min articular cartilage cells13. The ﬁndings of premature se-
nescence and apoptotic acceleration in OA substantiate
that the disease is age dependent, mechanically driven,
and chemically, particularly ROS-mediated.Role of synovium
It is now widely accepted that not only is OA more than
a disease of cartilage, but that it is a failure of the whole
joint, which leads to and perpetuates the disease pro-
cesses. The classiﬁcation of OA as a non-inﬂammatory ar-
thritis is in part due to the low synovial ﬂuid leukocytearrow lesions and subchondral cysts.
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fusions, and stiffness) clearly reﬂects synovial inﬂammation,
implicating it as a low-grade contributor in disease patho-
genesis. Synovitis occurs even in early OA and can be sub-
clinical, as arthroscopic studies suggest that localized
proliferative and inﬂammatory changes of the synovium oc-
cur in up to 50% of OA patients e many of whom do not ap-
pear to have active inﬂammation14. Newer, more powerful
imaging techniques using 3 T magnetic resonance imaging
(MRI) scanning have also strengthened the concept that sy-
novial inﬂammation is more common than may have been
previously appreciated. Our recent work has revealed local-
ized areas of synovitis, which may not be detectable either
on physical exam or using other modalities such as ultra-
sound (Fig. 2). In addition, in a cross-sectional study, we
found that increasing synovial volume, as detected on ga-
dolinium-enhanced MRI, correlates with the severity of
knee OA by KL score, as well as with joint space narrow-
ing15. Synovial histological changes include synovial hyper-
trophy and hyperplasia with an increased number of lining
cells, often accompanied by inﬁltration of the sublining tis-
sue with scattered foci of lymphocytes. In contrast to rheu-
matoid arthritis (RA), synovial inﬂammation in OA is mostly
conﬁned to areas adjacent to pathologically damaged carti-
lage and bone. This activated synovium can release pro-
teinases and cytokines that may accelerate destruction of
nearby cartilage.
The synovium produces some of the chemokines and
metalloproteinases that degrade cartilage, even though
the cartilage itself produces most of these destructive mol-
ecules in a vicious autocrine and paracrine fashion. In
turn, cartilage breakdown products, resulting from mechan-
ical or enzymatic destruction, can provoke the release of
collagenase and other hydrolytic enzymes from synovial
cells and lead to vascular hyperplasia in OA synovial mem-
branes. Generally, inﬂammation and angiogenesis often ac-
company each other, and this seems to be no different in
the OA joint, where inﬂammation facilitates angiogenesis
and angiogenesis then potentiates inﬂammation. Inﬂamma-
tory cells such as macrophages not only secrete pro-angio-
genic factors, but also secrete factors that stimulate other
cells, such as endothelial cells and ﬁbroblasts, to produce
vascular endothelial growth factor (VEGF), basic ﬁbroblast
growth factor (bFGF) and other factors that further promote
angiogenesis. Then, the blood vessel permeability and up-
regulation of adhesion molecules that are seen as part of
angiogenesis perpetuates the inﬂammatory response. Addi-
tionally, a new road map is created to continue to transport
these inﬂammatory cells and nutrients to the sites of
inﬂammation16.
OA is by far the most common type of arthritis encoun-
tered worldwide, yet the development of effective disease-
modifying treatments continues to lag behind that of the
inﬂammatory arthritides. Current goals that are still to beachieved include understanding better how the numerous
multi-factorial forces (e.g., genetic, biomechanical, hor-
monal, etc.) converge to manifest the OA phenotype and
improving identiﬁcation of patients at risk of clinically mean-
ingful progression, by using growing knowledge of the epi-
demiological, genetic, biochemical and imaging ﬁndings,
perhaps even in a combinatorial manner. As the pathogen-
esis of OA is further elucidated, and the discovery of im-
proved biomarkers continues, we hope to see true
DMOADs emerge in the near future.
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